A man with a blue saftey hat on and a light beard sprinkled with white hair smiling looking at the camera. A man with a blue saftey hat on and a light beard sprinkled with white hair smiling looking at the camera.

Results from
Clinical Trials

"My doctor said that AUSTEDO can be taken with most mental health medications."

Model is not an actual patient

In clinical studies, AUSTEDO (deutetrabenazine) tablets reduced tardive dyskinesia (TD) symptoms while people continued on their mental health medications.1,2

My doctor said, ‘I have news for you. There's a drug on the market called AUSTEDO, and it's for tardive dyskinesia.’

—Carol, TD Patient Individual results may vary

Professional Insights

AUSTEDO: A Treatment for Tardive Dyskinesia

Hear professionals discuss the
benefit of treating tardive dyskinesia with AUSTEDO.

Cover image for a professional insight video talking about AUSTEDO® (deutetrabenazine), a treatment for tardive dyskinesia. Cover image for a professional insight video talking about AUSTEDO® (deutetrabenazine), a treatment for tardive dyskinesia.

AUSTEDO reduced the involuntary, repetitive, uncontrolled movements of TD in 2 clinical studies.

– STUDY #1 –

Involuntary movement reduction at week 121,3

%
TAKING AUSTEDO
vs
%
TAKING PLACEBO
AUSTEDO® (deutetrabenazine) tablets Clinical Study Reduced AIMS* Score Created with Sketch. placebo AUSTEDO
  • AUSTEDO reduced the AIMS total score by
    3.3 points vs 1.4 points with placebo from the start of the study.
  • For participants taking AUSTEDO, this represents a 33% reduction in AIMS total score vs a 12% reduction for those taking placebo.
  • Improvement in uncontrolled movements began to be seen at 2 weeks.

– STUDY #2 –

Involuntary movement reduction at week 121

%
TAKING AUSTEDO
vs
%
TAKING PLACEBO
AUSTEDO® (deutetrabenazine) tablets Clinical Study Created with Sketch. placebo AUSTEDO
  • AUSTEDO reduced the AIMS total score by 3.0 points vs 1.6 points with placebo.
  • This represents an approximately 27% reduction in AIMS total score for people taking AUSTEDO vs a 16% reduction for those taking placebo.

A reduction in AIMS total score means reduced involuntary movements.1

Understanding aims

It’s time to explore

Talking to your doctor about austedo

Man with brown bag strap over shoulder while holding a piece of mail over a counter.

Model is not an actual patient

Man standing in locker room with a blue locker open and leaning on the door with a yellow safety vest on smiling at the camera.

Model is not an actual patient

personalized dosing

financial support with austedo

Man looking through a stack of papers wearing a safety hat and neon yellow safety vest, on a webpage that discusses td treatment.

Model is not an actual patient

You are about to leave this site

You are about to leave AUSTEDO.com and enter a website operated by a third party. Teva is not responsible for and does not control the content contained on this third-party website linked to AUSTEDO.com.

Are you a healthcare professional?

The information on this site is intended for healthcare professionals in the United States. Are you a healthcare professional in the United States?

References: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information Parsippany, NJ. Teva Neuroscience, Inc. 2. Data on file. Parsippany, NJ. Teva Neuroscience, Inc. 3. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595-604. Published online June 28, 2017. doi: 10.1016/S2215-0366(17)30236-5